Abstract

AN OVERVIEW ON PHARMACOGENOMICS

Aashutosh Sinwal*, Ishu, Fareed, Sana Goher, Neha Rangwar, Dhanadevan K. S.

.

Abstract

Pharmacogenomics examines the effects of medications on the human body as a function of heredity. This field is the meeting point of genetics and medicines; the name derives from the phrases genomics and pharmacology. The field of pharmacogenetics (PGx) was launched in 1866 with the establishment of the principles of heredity. Testing should be taken into account whenever these 250+ medications are being examined since the FDA has released PGx testing recommendations. Mental health, cardiovascular health, and pain management are just a few of the medical specialties that offer PGx recommendations. There are several comparable therapeutic choices for antidepressant medicines, making them an ideal candidate for the usage of PGx. Since pharmacogenomics is still in its infancy, pharmaceutical companies are understandably wary about using it in clinical studies. Numerous benefits can be achieved by combining pharmacogenomic testing with clinical trials. Pharmacogenetics may also be useful for identifying populations with risk factors that are unrelated to the medicine itself. A patient's pharmacogenetic status is now used to advise treatment regimens for cancer chemotherapy and oral anticoagulants. Pharmacogenetic approaches are progressively supplanting the ageold practice of relying on trial and error when dosing a patient. Drug research and development can also use pharmacogenetics, which is currently used in therapies.

Keywords: Pharmacogenetics, Single nucleotide polymorphisms, Adverse drug events, Pharmaceutical.